VNDAVanda Pharmaceuticals Inc.
Pharmaceutical Preparations
- Revenue
- $216M
- 8.7% YoY
- Operating margin
- -70.0%
- 242% YoY
- EBITDA
- −$150M
- 277% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $269M | $254M | $193M | $199M | $216M | 8.7% |
| Operating income | $42M | $6M | −$14M | −$41M | −$151M | 272% |
| Net income | $33M | $6M | $3M | −$19M | −$221M | 1067% |
| Operating cash flow | $64M | $32M | $13M | −$16M | −$109M | 595% |
| Capex | $552K | $679K | $383K | $490K | $998K | 104% |
| Stock-based comp | $15M | $16M | $14M | $12M | $9M | 24% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $4M | $8M | 67 | 120 |
| FY2024 | $4M | $4M | 36 | 91 |
| FY2023 | $4M | $2M | 32 | 92 |
| FY2022 | $4M | $860K | 56 | 89 |
| FY2021 | $6M | $6M | 119 | 99 |